Song Lin

Biography

Song Lin, M.Sc., Director of Drug Metabolism and Pharmacokinetics, has been with Alliance Pharma since 2012. In this role, he closely works with biotechnology and pharmaceutical companies to build strategic outsourcing partnerships for discovery preclinical services, regulated bioanalysis for submissions, and clinical development projects. Prior to joining Alliance, Mr. Lin worked as the head of Drug Metabolism Laboratories at Novartis Institutes of Biomedical Research in Emeryville, California He has also held roles at Chiron Corporation, COR Therapeutics Inc., Covance Laboratories, and Phoenix International Life Sciences, Inc. Mr. Lin received his M.Sc. degree in Biology and Plant Anatomy at the Sun Yatsen University in Guangzhou, China. He subsequently earned his second M.Sc. degree in Biochemistry at the University of Alberta, in Edmonton, Canada. Notably, Mr. Lin has presented at NIH, Novartis Global Discovery Chemistry Congress, and the Society of Toxicology Annual meetings. His most recent publication entitled, “3D Pharmacophore Model-Assisted Discovery of Novel CDC7 Inhibitors” was published in 2011 in ACS Medicinal Chemistry Letters.         Song Lin, M.Sc., Director of Drug Metabolism and Pharmacokinetics, has been with Alliance Pharma since 2012. In this role, he closely works with biotechnology and pharmaceutical companies to build strategic outsourcing partnerships for discovery preclinical services, regulated bioanalysis for submissions, and clinical development projects. Prior to joining Alliance, Mr. Lin worked as the head of Drug Metabolism Laboratories at Novartis Institutes of Biomedical Research in Emeryville, California He has also held roles at Chiron Corporation, COR Therapeutics Inc., Covance Laboratories, and Phoenix International Life Sciences, Inc. Mr. Lin received his M.Sc. degree in Biology and Plant Anatomy at the Sun Yatsen University in Guangzhou, China. He subsequently earned his second M.Sc. degree in Biochemistry at the University of Alberta, in Edmonton, Canada. Notably, Mr. Lin has presented at NIH, Novartis Global Discovery Chemistry Congress, and the Society of Toxicology Annual meetings. His most recent publication entitled, “3D Pharmacophore Model-Assisted Discovery of Novel CDC7 Inhibitors” was published in 2011 in ACS Medicinal Chemistry Letters.        

Research Interest

Host defense mechanisms,LPS effects on neurotransmitters